MedTrace Logo

The STRIVE Study: Development of a Blood Test for Early Detection of Multiple Cancer Types

NCT03085888 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99481

Last updated 2024-09-20

No results posted yet for this study

Summary

GRAIL is using high-intensity sequencing of circulating cell-free nucleic acids (cfNAs) to develop blood tests to detect cancer early. The purpose of this study is to validate the ability of the pre-specified GRAIL Test to detect breast cancer and other invasive cancers, including hematologic malignancies, that will occur within one year of the first study blood draw.

Conditions

Sponsors & Collaborators

  • GRAIL, Inc.

    lead INDUSTRY

Principal Investigators

  • GRAIL Study Director · GRAIL, Inc.

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-28
Primary Completion
2022-06-30
Completion
2024-04-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03085888 on ClinicalTrials.gov